Living with AAV: Monitoring and Your Future Health
At a Glance
After reaching AAV remission, long-term monitoring is essential due to the high risk of relapse. Survivorship involves routine labs every 3 to 6 months, recognizing emergency flare symptoms like coughing blood, and managing medication side effects to maintain quality of life.
Reaching remission is a major milestone, but for many patients, it marks the beginning of a new phase: survivorship. Because AAV is a chronic condition with a high risk of returning (relapse), life after the initial “storm” requires a shift toward long-term vigilance and quality-of-life management [1].
Understanding the Risk of Relapse
A relapse occurs when the immune system mistakenly reactivates and begins attacking blood vessels again. While everyone’s journey is different, certain factors influence this risk:
- Antibody Type: Patients with PR3-ANCA (often seen in GPA) generally have a higher risk of relapse compared to those with MPO-ANCA [2][3].
- Maintenance Choice: Staying on maintenance therapy, particularly rituximab, has been shown to significantly lower the risk of the disease returning [4][5].
- Infections: Sometimes, common infections (like Staph in the nose) can act as a trigger for a GPA flare [6].
Your Monitoring Roadmap
Regular check-ups are the “early warning system” for AAV. While there is no single schedule that fits every person, most monitoring plans include:
- Standard Labs (Every 3–6 Months):
- The ANCA Question: Your doctor may track your ANCA levels. However, a rise in ANCA doesn’t always mean a relapse is happening—it is just one piece of the puzzle that must be weighed against how you feel [7][9].
- Emerging Markers: You may read about newer biomarkers like calprotectin (S100A8/A9) and Pentraxin-3 (PTX3). It is important to know that these are currently used mostly in research settings to predict relapses; they are not yet standard tests available at most commercial labs [9][10].
Self-Monitoring: Red Flags to Watch For
You are the best expert on your own body. However, distinguishing between normal aches and pains, medication side effects, and an actual disease flare is critical.
Go to the Emergency Room IMMEDIATELY if you experience:
- Coughing up blood (hemoptysis).
- Sudden, severe shortness of breath.
- A sudden high fever, especially while taking immunosuppressants (as this can indicate a life-threatening infection).
- Sudden loss of vision.
Call your Clinic/Doctor’s Office if you experience:
- New or worsening numbness, tingling, or “pins and needles” in your hands or feet [11].
- “Crusting” or bloody discharge from the nose that doesn’t resolve [7].
- Unexplained extreme fatigue that doesn’t improve with rest, or new, persistent skin rashes [7].
Living Well: Quality of Life
Survivorship isn’t just about the absence of disease; it’s about feeling well. Many AAV patients face long-term challenges such as:
- Managing Steroid Side Effects: Long-term prednisone use is a massive hurdle. It can thin your bones (osteoporosis), increase your blood sugar, and impact your mood. Work with your doctor on practical lifestyle habits: taking Calcium and Vitamin D supplements, engaging in weight-bearing exercises, and monitoring your sugar intake [1][12].
- Fatigue: This is one of the most common complaints and can persist even when the disease is in remission [11]. Listen to your body and pace yourself.
- Mental Health: “Scanxiety”—the anxiety that occurs before lab results—is real. Acknowledging the psychological weight of a chronic rare disease is essential for long-term health [11].
Newer treatments, such as avacopan, are showing promise not just in treating the disease, but in improving overall quality of life by reducing the “toxic” burden of older medications [13]. Staying connected with a multidisciplinary team—including rheumatologists, nephrologists, and potentially a therapist—ensures you are supported in every aspect of your recovery [14].
Common questions in this guide
Does a rise in ANCA levels mean my vasculitis is relapsing?
What are the emergency warning signs of an AAV flare?
How often do I need lab work when my AAV is in remission?
Does my antibody type affect my risk of AAV relapse?
How can I protect my bones while taking long-term steroids for AAV?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Am I PR3-ANCA or MPO-ANCA positive, and how does that influence my specific risk for relapse?
- 2.What is the ideal schedule for my routine blood work and urinalysis over the next year?
- 3.If my ANCA levels rise but I feel fine, will we change my treatment, or do we wait for physical symptoms?
- 4.How will we monitor for the long-term side effects of my medications, such as bone density scans for osteoporosis?
- 5.What daily supplements (like calcium and Vitamin D) should I be taking to protect my bones while on steroids?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (14)
- 1
[Granulomatosis with polyangiitis: what's new?]
Ringwald M, Chevalley D, Bongard C, et al.
Revue medicale suisse 2023; (19(821)):674-679 doi:10.53738/REVMED.2023.19.821.674.
PMID: 37017349 - 2
Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive Granulomatosis With Polyangiitis (Wegener's) Is a Clinically Distinct Subset of ANCA-Associated Vasculitis: A Retrospective Analysis of 315 Patients From a German Vasculitis Referral Center.
Schirmer JH, Wright MN, Herrmann K, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2016; (68(12)):2953-2963 doi:10.1002/art.39786.
PMID: 27333332 - 3
Proteinase 3-specific antineutrophil cytoplasmic antibody-associated vasculitis.
Falde SD, Fussner LA, Tazelaar HD, et al.
The Lancet. Rheumatology 2024; (6(5)):e314-e327 doi:10.1016/S2665-9913(24)00035-3.
PMID: 38574742 - 4
Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B, Pagnoux C, Perrodeau É, et al.
Annals of the rheumatic diseases 2018; (77(8)):1150-1156 doi:10.1136/annrheumdis-2017-212768.
PMID: 29724729 - 5
Development and Validation of a Simulation Model for Treatment to Maintain Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Wallace ZS, Stone JH, Fu X, et al.
Arthritis care & research 2023; (75(9)):1976-1985 doi:10.1002/acr.25088.
PMID: 36645017 - 6
Update on the epidemiology, risk factors, and outcomes of systemic vasculitides.
Berti A, Dejaco C
Best practice & research. Clinical rheumatology 2018; (32(2)):271-294 doi:10.1016/j.berh.2018.09.001.
PMID: 30527432 - 7
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Chung SA, Langford CA, Maz M, et al.
Arthritis care & research 2021; (73(8)):1088-1105 doi:10.1002/acr.24634.
PMID: 34235880 - 8
Factors associated with pauci-immune glomerulonephritis in patients undergoing kidney biopsy with positive anti-neutrophil cytoplasmic antibody results.
Lee YJ, Lee J, Ahn SM, et al.
Journal of nephrology 2025; (38(9)):2919-2928 doi:10.1007/s40620-025-02430-2.
PMID: 41091444 - 9
Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Pepper RJ, Draibe JB, Caplin B, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2017; (69(1)):185-193 doi:10.1002/art.39814.
PMID: 27428710 - 10
Pentraxin-3 - a potential biomarker in ANCA-associated vasculitis.
Jonasdottir AD, Antovic A, Qureshi AR, et al.
Scandinavian journal of rheumatology 2023; (52(3)):293-301 doi:10.1080/03009742.2022.2045790.
PMID: 35383519 - 11
ANCA-Associated Vasculitic Neuropathies: A Review.
Koike H, Nishi R, Ohyama K, et al.
Neurology and therapy 2022; (11(1)):21-38 doi:10.1007/s40120-021-00315-7.
PMID: 35044596 - 12
Highlights from the breakout session: optimising new treatments.
Francis L, Dhutia A, Pusey C, Jones RB
Rheumatology (Oxford, England) 2025; (64(Supplement_1)):i117-i119 doi:10.1093/rheumatology/keae426.
PMID: 40071420 - 13
The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial.
Strand V, Jayne DRW, Horomanski A, et al.
The Lancet. Rheumatology 2023; (5(8)):e451-e460 doi:10.1016/S2665-9913(23)00092-9.
PMID: 38251577 - 14
Granulomatosis With Polyangiitis: A Clinical Case.
Rodrigues F, Oliveira Sá AI, Mendes M, et al.
Cureus 2022; (14(12)):e32410 doi:10.7759/cureus.32410.
PMID: 36636531
This page provides information on managing AAV survivorship for educational purposes only. Always consult your rheumatologist or nephrologist regarding your specific monitoring schedule and symptoms.
Get notified when new evidence is published on Anti-neutrophil cytoplasmic antibody-associated vasculitis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.